Cell-Based Treatment for Dry AMD: Advanced Cell Technology (ACT)


Description: ACT has launched a Phase I/II clinical trial of transplanted retinal pigment epithelial (RPE) cells for the treatment of dry age-related macular degeneration. The RPE cells are derived from human stem cells. RPE are the first cells affected in people with dry AMD. They play a critical role in maintaining the health and function of photoreceptors. The study, taking place at the Jules Stein Eye Institute at the University of California, Los Angeles, will enroll up to 12 participants. The Foundation funded many of the preclinical studies that made this human trial possible.

Trial status: Recruiting participants.

Partial List of Participation Criteria:

  1. 55 years of age or older
  2. Diagnosis of advanced dry macular degeneration (geographic atrophy)
  3. The visual acuity of the eye to receive the transplant will be no better than 20/400
  4. The visual acuity of the eye that is NOT to receive the transplant will be no worse than 20/400

Clinical Contact:
Logan Hitchcock
(310) 825-3046
Jules Stein Eye Institute, UCLA
Los Angeles, CA

Bascom Palmer Eye Institute
Miami, Florida
Contact: Cristy M Lage-Rodriguez, M.S., C.C.R.C

Wills Eye Institute-Mid Atlantic Retina
Philadelphia, Pennsylvania
Contact: Shellie Markun


Clinical Trials Underway for Stem Cell Treatments

Additional Information:
ACT stem cell clinical trial for dry AMD listing on ClinicalTrials.gov